# PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

> **NCT01441414** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** PF-04856884
- **DRUG:** Axitinib (AG-013736)
- **DRUG:** Axitinib (AG-013736)

## Key facts

- **NCT ID:** NCT01441414
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11-21
- **Primary completion:** 2014-03-27
- **Final completion:** 2014-03-27
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01441414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01441414, "PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01441414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*